Navigation Links
YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
Date:10/5/2009

MISSISSAUGA, ON, Oct. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today announced it has proposed to merge Cytopia Ltd., a clinical-stage, Melbourne-based drug development company, into YM. Cytopia's lead products are CYT997, a novel vascular disrupting agent (VDA) currently in Phase II trials, and CYT387, a novel, orally-active JAK2 inhibitor that recently received clearance from the FDA to commence a Phase I trial in myeloproliferative disorders.

"After assessing numerous global in-licensing opportunities, we determined that Cytopia's products were an ideal complement to our current portfolio," said David Allan, Chairman and CEO of YM BioSciences. "While the continued development of our lead product nimotuzumab remains our highest priority, we believe the timing is appropriate to expand our pipeline, consistent with our business model, leveraging our existing resources and expertise to select from the opportunities offered to us in order to continue to enhance the value of YM."

Cytopia's lead product, CYT997, has demonstrated potent disruption of existing tumor vasculature and therefore has the potential to synergize with existing marketed anti-angiogenesis agents, such as Avastin(R), which only target novel blood vessel formation. CYT997's availability in both oral and intravenous formulations differentiates it from most other VDAs, including those more advanced in clinical development, which are typically available in intravenous form only. Phase I trial results from the intravenous formulation of CYT997 were presented at ASCO in 2008 and results from the Phase I oral study were presented at ASCO 2009 demonstrating that both formulations were well-tolerated and showed preliminary signs of efficacy as determined by measures of tumor v
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... and its potential to revolutionize the world has ... multinational corporations and small start-ups. The early years ... research projects largely due to the high risks ... Government budgets earmarked for this evolving technology have ...
(Date:9/19/2014)... SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ ... announced results from preclinical studies characterizing the analgesic ... oral, peripherally-acting kappa opioid receptor agonist molecules. The ... molecule polymer medicinal chemistry platform. The ... described in the medical literature. 1,2 Kappa ...
(Date:9/19/2014)... 19, 2014 Barnhardt Manufacturing Company ... for its Organic Cotton . The USDA Certified ... renewable biobased ingredients meets or exceeds levels set by ... in whole or in significant part of agricultural, forestry, ... our Organic cotton to be immediately identified as a ...
(Date:9/19/2014)... -- , The first grants awarded to ... (ESPE) Meeting  Investment supports innovative projects for ... field of growth  , EMD Serono, a ... , today announced the first recipients of the Grant ... announced during a Satellite Symposium organized by EMD Serono ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... , , HUNTERSVILLE, N.C., ... leader in built-in antimicrobial product protection, has partnered with YogaDirect.com, ... the U.S., to launch the first ever line of yoga ... of yoga mats that will stay cleaner and fresher for ...
... , DOYLESTOWN, Pa., July 28 ... company to offer a broad range of accredited CME courses in ... clinical trials. , , The comprehensive education and ... Institute (BRITI)(TM). RadMD is partnering with International Center for Postgraduate Medical ...
... , , WESTFORD, Mass., July ... manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial ... Second Quarter 2009 Financial Results , , ... with $39.2 million in the same period of 2008 and $14.8 million in ...
Cached Biology Technology:Microban Partners With YogaDirect.com to Launch Yoga Mats With Zinc Antimicrobial Technology 2RadMD First to Offer CME-Certified Education and Training For Medical Imaging in Clinical Trials 2Cynosure Reports Second Quarter 2009 Financial Results 2Cynosure Reports Second Quarter 2009 Financial Results 3Cynosure Reports Second Quarter 2009 Financial Results 4Cynosure Reports Second Quarter 2009 Financial Results 5Cynosure Reports Second Quarter 2009 Financial Results 6Cynosure Reports Second Quarter 2009 Financial Results 7Cynosure Reports Second Quarter 2009 Financial Results 8Cynosure Reports Second Quarter 2009 Financial Results 9Cynosure Reports Second Quarter 2009 Financial Results 10Cynosure Reports Second Quarter 2009 Financial Results 11Cynosure Reports Second Quarter 2009 Financial Results 12Cynosure Reports Second Quarter 2009 Financial Results 13
(Date:9/18/2014)... researchers from McGill University and the Quebec government ... ,microbeads, Canadian Journal of Fisheries and Aquatic ... cosmetics, household cleansers, or industrial cleansers, to which ... their small size and buoyancy, they may readily ... a global contaminant in the world,s oceans, but ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, it,s ... creatures. , But by using a signaling ... alter their behavior to suit their population. In ... are present, and act accordingly. , Once the ... may change from innocuous to pathogenic, or from ...
(Date:9/18/2014)... language is unique to humans. "The genetic changes that ... evolution to make this possible are largely unknown, but ... says Wolfgang Enard, Professor of Anthropology and Human Biology ... biological basis of language Enard has now taken an ... undertaken in collaboration with scientists at several universities, including ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... University Feinberg School of Medicine played a significant ... Abraxane (paclitaxel protein-bound particles for injectable suspension), indicated ... approval means that women with metastatic breast cancer ... with solvents and will no longer need steroid ...
... In laboratory mouse experiments, researchers at The University of ... way to use RNA interference (RNAi) so that it ... activated STAT3, a crucial gene found in some human ... invasive. , The study, presented at the annual meeting ...
... provide for study of human immune responses, scientists have ... rapid immune response by two separate armies of defensive ... microbes like the leprosy bug, this initial defense sometimes ... yields to a dangerous, spreading infection. , Led by ...
Cached Biology News:Nanoparticle Breast Cancer Drug Approved by FDA 2Used in a new way, RNA interference permanently silences key breast cancer gene 2Leprosy microbes lead scientists to immune discovery 2
... The four-bay DNA Engine Tetrad ... of interchangeable Alpha units (sample-holder, heat-pump ... numbers of vessels. A Pentium-class computer ... displays current block, sample, and lid ...
Printer paper for Model 680 series readers is used with the thermal printers of the Model 680 and Model 680 XR microplate readers. Supplied as 2 rolls....
... for 2-D separations. The cell has a six-gel ... xi multi-cell can be customized for several parameters: ... cooling system. The PROTEAN II xi multi-cell can ... multi-cell for a wider format that accommodates 17 ...
... is tailored to highly enrich ... rat spleen cells. Cells are ... compatible 0.5 Tesla) immunomagnetic negative ... content of the enriched fraction ...
Biology Products: